150 related articles for article (PubMed ID: 27809798)
1. Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies.
Biaoxue R; Hua L; Wenlong G; Shuanying Y
BMC Cancer; 2016 Nov; 16(1):836. PubMed ID: 27809798
[TBL] [Abstract][Full Text] [Related]
2. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
Liu B; Zhao Y; Yuan J; Zeng L; Sun R; Meng X; Yang S
PLoS One; 2017; 12(11):e0187860. PubMed ID: 29182642
[TBL] [Abstract][Full Text] [Related]
3. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
4. A Pair-Wise Meta-Analysis Highlights Serum Amyloid Has A Potential Clinical Value for Diagnosis and Prognosis Prediction of Gastric Cancer.
Zhang Y; Chang Y; Su P; Wang X
Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255296
[TBL] [Abstract][Full Text] [Related]
5. Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum.
Dai S; Wang X; Liu L; Liu J; Wu S; Huang L; Xiao X; He D
Sci China C Life Sci; 2007 Jun; 50(3):305-11. PubMed ID: 17609886
[TBL] [Abstract][Full Text] [Related]
6. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.
Dowling P; Clarke C; Hennessy K; Torralbo-Lopez B; Ballot J; Crown J; Kiernan I; O'Byrne KJ; Kennedy MJ; Lynch V; Clynes M
Int J Cancer; 2012 Aug; 131(4):911-23. PubMed ID: 21953030
[TBL] [Abstract][Full Text] [Related]
7. Association between serum amyloid A levels and cancers: a systematic review and meta-analysis.
Zhou J; Sheng J; Fan Y; Zhu X; Tao Q; He Y; Wang S
Postgrad Med J; 2018 Sep; 94(1115):499-507. PubMed ID: 30341230
[TBL] [Abstract][Full Text] [Related]
8. Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A.
Kanoh Y; Abe T; Masuda N; Akahoshi T
Oncol Rep; 2013 Feb; 29(2):469-73. PubMed ID: 23135313
[TBL] [Abstract][Full Text] [Related]
9. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis.
Cho WC; Yip TT; Cheng WW; Au JS
Br J Cancer; 2010 Jun; 102(12):1731-5. PubMed ID: 20502455
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer.
Zhang XY; Zhang G; Jiang Y; Liu D; Li MZ; Zhong Q; Zeng SQ; Liu WL; Zeng MS
Chin J Cancer; 2015 Aug; 34(8):335-49. PubMed ID: 26264146
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.
Khan N; Cromer CJ; Campa M; Patz EF
Cancer; 2004 Jul; 101(2):379-84. PubMed ID: 15241837
[TBL] [Abstract][Full Text] [Related]
12. Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression.
Li Z; Hou Y; Zhao M; Li T; Liu Y; Chang J; Ren L
J Ovarian Res; 2020 Jun; 13(1):67. PubMed ID: 32517794
[TBL] [Abstract][Full Text] [Related]
13. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer.
Liu DH; Wang XM; Zhang LJ; Dai SW; Liu LY; Liu JF; Wu SS; Yang SY; Fu S; Xiao XY; He DC
Biomed Environ Sci; 2007 Feb; 20(1):33-40. PubMed ID: 17458139
[TBL] [Abstract][Full Text] [Related]
14. Serum amyloid a as a predictive marker for radiation pneumonitis in lung cancer patients.
Wang YS; Chang HJ; Chang YC; Huang SC; Ko HL; Chang CC; Yeh YW; Jiang JS; Lee CY; Chi MS; Chi KH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):791-7. PubMed ID: 22836061
[TBL] [Abstract][Full Text] [Related]
15. Serum microRNA-21 as a diagnostic marker for lung carcinoma: a systematic review and meta-analysis.
Yang X; Guo Y; Du Y; Yang J; Li S; Liu S; Li K; Zhang D
PLoS One; 2014; 9(5):e97460. PubMed ID: 24865991
[TBL] [Abstract][Full Text] [Related]
16. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis.
Biran H; Friedman N; Neumann L; Pras M; Shainkin-Kestenbaum R
J Clin Pathol; 1986 Jul; 39(7):794-7. PubMed ID: 3734116
[TBL] [Abstract][Full Text] [Related]
17. A combined biomarker pattern improves the discrimination of lung cancer.
Liu L; Liu J; Wang Y; Dai S; Wang X; Wu S; Wang J; Huang L; Xiao X; He D
Biomarkers; 2011 Feb; 16(1):20-30. PubMed ID: 20964562
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer.
Sung HJ; Ahn JM; Yoon YH; Rhim TY; Park CS; Park JY; Lee SY; Kim JW; Cho JY
J Proteome Res; 2011 Mar; 10(3):1383-95. PubMed ID: 21141971
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the diagnostic accuracy of plasma markers for early diagnosis in patients suspected for acute appendicitis.
Schellekens DH; Hulsewé KW; van Acker BA; van Bijnen AA; de Jaegere TM; Sastrowijoto SH; Buurman WA; Derikx JP
Acad Emerg Med; 2013 Jul; 20(7):703-10. PubMed ID: 23859584
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic rather than prognostic markers-relationship between EpCAM overexpression and lung cancer: a meta-analysis.
Zhu T; Peng X; Cheng Z; Xing D; Zhang M
Ann Palliat Med; 2021 Apr; 10(4):4025-4036. PubMed ID: 33832309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
